All Stories

Former Inhibikase leader launches new biotech for midstage Parkinson's asset

The founder and former leader of Inhibikase Therapeutics is blazing a new biotech trail in an effort to get a beleaguered Parkinson’s candidate over the finish line.

May 13, 2025 - 21:44
 0
Former Inhibikase leader launches new biotech for midstage Parkinson's asset
The founder and former leader of Inhibikase Therapeutics is blazing a new biotech trail in an effort to get a beleaguered Parkinson’s candidate over the finish line.
Read More

Tags:

Previous Article

AbbVie remains king in doctors' perception of immunology drugmakers, but J&J reg...

Next Article

UnitedHealth shares plunge further as chief Andrew Witty steps down

Related Posts

Roche to spend $550M building Indianapolis HQ into CGM production hub

Roche to spend $550M building Indianapolis HQ into CGM ...

May 13, 2025  0

FDA will fully adopt generative AI by end of June, Martin Makary says

FDA will fully adopt generative AI by end of June, Mart...

May 8, 2025  0

Vertex pauses Moderna-partnered cystic fibrosis trial, takes $379M hit tied to separate program

Vertex pauses Moderna-partnered cystic fibrosis trial, ...

May 8, 2025  0